3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
27
Neoplasm Metastasis
9
Stomach Neoplasms
7
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Sarcoma
2
Salivary Gland Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Advanced Breast Cancer
2
Adenocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Interventions
Paclitaxel
10
Carboplatin
6
Bevacizumab
5
pembrolizumab
4
Cyclophosphamide
4
olaparib
3
liposomal doxorubicin
3
fludarabine
3
ribociclib
2
palbociclib
2
mirvetuximab soravtansine
2
Topotecan
2
Nivolumab
2
Letrozole
2
Fulvestrant
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pegfilgrastim
1
niraparib
1
lenvatinib
1
isoquercitrin
1
fludarabine phosphate
1
durvalumab
1
cemiplimab
1
abemaciclib
1
Tinzaparin
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
SLC25A33 protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Ovarian Epithelial
×
trastuzumab deruxtecan
×
Clear all
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled